Henderson, United States
Corstasis Therapeutics, founded in 2018, is a clinical-stage pharmaceutical company based in the United States. The firm is focused on advancing innovative outpatient options for patients grappling with fluid overload, or edema, which is commonly associated with conditions like congestive heart failure (CHF), liver, and kidney disease.
With a strong emphasis on addressing unmet clinical needs, the company operates under the slogan, "Advancing Options for Patients Suffering from Edema Associated with Congestive Heart Failure, Liver, and Kidney Disease." This highlights its dedicated approach towards improving quality of life for affected patients through cutting-edge treatments.
The most recent financial backing for Corstasis Therapeutics came on 01 June 2023 from Triton Funds. While the specific amount of this investment remains undisclosed, the involvement of a credible investor underscores confidence in the company's direction and growth potential in the pharmaceutical sector.
